Vascular Disruption by EBC-46: How Tigilanol Tiglate Starves Tumours of Blood Supply
EBC-46 triggers rapid collapse of tumour vasculature through PKC-mediated endothelial disruption, cutting off nutrient supply and accelerating tumour necrosis within hours.
One of the most striking features of EBC-46 (tigilanol tiglate) in preclinical and early clinical studies is the speed at which treated tumours lose their blood supply. Within hours of intratumoral injection, tumour vasculature collapses — a phenomenon known as vascular disruption — leading to rapid haemorrhagic necrosis. Understanding this mechanism helps explain why EBC-46 has attracted significant research interest as a potential oncology compound.
The Tumour Vascular Network
Solid tumours depend on angiogenesis — the formation of new blood vessels — to sustain their growth. Tumour vasculature, however, is structurally abnormal: vessels are poorly formed, leaky, and more vulnerable to disruption than normal tissue vasculature. This structural weakness is precisely what EBC-46 exploits. Published research from QBiotics Group and collaborating institutions has documented how tigilanol tiglate targets this vulnerability selectively.
PKC Activation and Endothelial Disruption
EBC-46 activates protein kinase C (PKC) isoforms, particularly PKC-delta and PKC-beta, in endothelial cells lining tumour blood vessels. This activation triggers a cascade of intracellular signalling events: increased endothelial permeability, disruption of cell-cell junctions, and ultimately, loss of vessel integrity. The result is a rapid haemorrhagic response — blood leaks from damaged vessels into the tumour mass, depriving cancer cells of oxygen and nutrients.
Research published in PLOS ONE demonstrated that this vascular disruption occurs within four hours of treatment in murine models, far faster than conventional anti-angiogenic therapies that typically take days or weeks to show measurable effects.
Haemorrhagic Necrosis: The Downstream Effect
Once tumour blood supply is compromised, the affected tissue undergoes necrosis — cell death driven by nutrient and oxygen deprivation rather than the programmed cell death (apoptosis) triggered by most chemotherapeutic agents. This necrotic response is visible macroscopically: treated tumours darken, soften, and are gradually replaced by granulation tissue as the body's wound-healing processes take over. The surrounding healthy tissue, with its structurally sound vasculature, remains largely unaffected.
Dual Mechanism: Vascular Disruption Plus Direct Cytotoxicity
Vascular disruption is not EBC-46's only mode of action. Research indicates that tigilanol tiglate also exerts direct cytotoxic effects on tumour cells through PKC-delta-mediated signalling, and recruits innate immune cells — particularly neutrophils — to the treatment site. This multi-pronged approach, combining vascular shutdown, direct cell killing, and immune recruitment, distinguishes EBC-46 from single-mechanism therapies and is a key reason researchers have pursued it through clinical development.
From Injectable to Oral: Open Questions
Published research on vascular disruption has focused on intratumoral injection of pharmaceutical-grade tigilanol tiglate. Whether oral blushwood berry extract supplements, which contain tigilanol tiglate alongside other seed constituents, produce any comparable vascular effects has not been studied in controlled clinical trials. Dietary supplements containing blushwood berry extract are sold under the DSHEA framework and are not intended to diagnose, treat, cure, or prevent any disease.
Related Articles
Explore the broader EBC-46 mechanism in our articles on the PKC-delta signalling pathway and neutrophil recruitment and tumour clearance.
